Is Allarity Therapeutics Inc. Common Stock a good investment? Allarity Therapeutics Inc. Common Stock (ALLR) is currently trading at 1.04 USD.
In terms of valuation, the stock trades at a P/E ratio of 0.12. This relatively low multiple may signal that Allarity Therapeutics Inc. Common Stock is undervalued compared to historical market norms.
Earnings Schedule: Allarity Therapeutics Inc. Common Stock is expected to release its next earnings report on Nov. 13, 2026. The market consensus estimate for Forward EPS is -0.86.
No, it does not currently pay a dividend.
Allarity Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be Nov. 13, 2026. The company currently has a trailing EPS of -0.79.
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.
| Split Date | Split Ratio to 1 |
|---|---|
| March 27, 2023 | 1:35 |
| June 29, 2023 | 1:40 |
| April 9, 2024 | 1:20 |
| Sept. 11, 2024 | 1:30 |
Community Discussion